Search

everythinglearnresearchcommunity

for

Search:↓

Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.

Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.

Androgen self-administration might be controlled by membrane receptors, not nuclear ones.

AH-001 could be a safer and more effective treatment for hair loss.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.

5α-reductase inhibitors may lower the risk of death from bladder cancer.

New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

Dutasteride makes alcohol less sedating and may lead to less drinking in men.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.

New compounds may help treat prostate issues without affecting androgen receptors.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

BPH treatments can cause sexual side effects affecting quality of life.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Surgery, especially prostatectomy, effectively reduces detrusor overactivity in bladder outlet obstruction patients.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Androgen, especially DHT, is crucial for erectile function in rats by affecting specific brain neurons.

5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.